Investor Presentation
68
Investor presentation
First six months of 2022
In STEP 5, people treated with semaglutide 2.4 mg sustained
their weight loss over 2 years
Clinically relevant and sustained weight loss in patients
% change in body
weight
with obesity or overweight
Data from STEP 5
-6
0 2 4 6 ∞
-2
-4
-8
-10
-12
-14
-16
-18
-20
Placebo: -0.6%
Semaglutide: -16.7%
08 16 24 32 40 48 56 64 72 80 88 96 104
Time since initiation (weeks)
Change in body weight in % depicts observed means since time of randomisation; trial product estimand; mean body weight: 106.0 kg
D
40% of patients lost ≥ 20% of their body
weight
Semaglutide appeared to have a safe and
well-tolerated profile
Improvements in lipid profiles as well as
C-reactive protein
Novo NordiskⓇView entire presentation